126 related articles for article (PubMed ID: 21544019)
1. An automated method for supporting busulfan therapeutic drug monitoring.
Juenke JM; Miller KA; McMillin GA; Johnson-Davis KL
Ther Drug Monit; 2011 Jun; 33(3):315-20. PubMed ID: 21544019
[TBL] [Abstract][Full Text] [Related]
2. Pretransplant conditioning in adults and children: dose assurance with intravenous busulfan.
Fisher VL; Barnes YJ; Nuss SL
Oncol Nurs Forum; 2006 Nov; 33(2):E36-43. PubMed ID: 16518436
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic drug monitoring is essential for intravenous busulfan therapy in pediatric hematopoietic stem cell recipients.
Malär R; Sjöö F; Rentsch K; Hassan M; Güngör T
Pediatr Transplant; 2011 Sep; 15(6):580-8. PubMed ID: 21736681
[TBL] [Abstract][Full Text] [Related]
4. Once-daily intravenous busulfan with therapeutic drug monitoring compared to conventional oral busulfan improves survival and engraftment in children undergoing allogeneic stem cell transplantation.
Bartelink IH; Bredius RG; Ververs TT; Raphael MF; van Kesteren C; Bierings M; Rademaker CM; den Hartigh J; Uiterwaal CS; Zwaveling J; Boelens JJ
Biol Blood Marrow Transplant; 2008 Jan; 14(1):88-98. PubMed ID: 18158965
[TBL] [Abstract][Full Text] [Related]
5. Busulfan dosing in children with BMIs ≥ 85% undergoing HSCT: a new optimal strategy.
Browning B; Thormann K; Donaldson A; Halverson T; Shinkle M; Kletzel M
Biol Blood Marrow Transplant; 2011 Sep; 17(9):1383-8. PubMed ID: 21288495
[TBL] [Abstract][Full Text] [Related]
6. High busulfan exposure is associated with worse outcomes in a daily i.v. busulfan and fludarabine allogeneic transplant regimen.
Geddes M; Kangarloo SB; Naveed F; Quinlan D; Chaudhry MA; Stewart D; Savoie ML; Bahlis NJ; Brown C; Storek J; Andersson BS; Russell JA
Biol Blood Marrow Transplant; 2008 Feb; 14(2):220-8. PubMed ID: 18215782
[TBL] [Abstract][Full Text] [Related]
7. Prospective validation of a novel IV busulfan fixed dosing for paediatric patients to improve therapeutic AUC targeting without drug monitoring.
Vassal G; Michel G; Espérou H; Gentet JC; Valteau-Couanet D; Doz F; Mechinaud F; Galambrun C; Neven B; Zouabi H; Nguyen L; Puozzo C
Cancer Chemother Pharmacol; 2008 Jan; 61(1):113-23. PubMed ID: 17393167
[TBL] [Abstract][Full Text] [Related]
8. Limited Sampling Strategies Supporting Individualized Dose Adjustment of Intravenous Busulfan in Children and Young Adults.
Teitelbaum Z; Nassar L; Scherb I; Fink D; Ring G; Lurie Y; Krivoy N; Bentur Y; Efrati E; Kurnik D
Ther Drug Monit; 2020 Jun; 42(3):427-434. PubMed ID: 31479045
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of once-daily IV busulfan as part of pretransplantation preparative regimens: a comparison with an every 6-hour dosing schedule.
Madden T; de Lima M; Thapar N; Nguyen J; Roberson S; Couriel D; Pierre B; Shpall EJ; Jones RB; Champlin RE; Andersson BS
Biol Blood Marrow Transplant; 2007 Jan; 13(1):56-64. PubMed ID: 17222753
[TBL] [Abstract][Full Text] [Related]
10. Busulfan in hematopoietic stem cell transplant setting.
McCune JS; Holmberg LA
Expert Opin Drug Metab Toxicol; 2009 Aug; 5(8):957-69. PubMed ID: 19611402
[TBL] [Abstract][Full Text] [Related]
11. Once-daily intravenous busulfan in children prior to stem cell transplantation: study of pharmacokinetics and early clinical outcomes.
Zwaveling J; den Hartigh J; Lankester AC; Guchelaar HJ; Egeler RM; Bredius RG
Anticancer Drugs; 2006 Oct; 17(9):1099-105. PubMed ID: 17001185
[TBL] [Abstract][Full Text] [Related]
12. Randomized trial of two different conditioning regimens for bone marrow transplantation in thalassemia--the role of busulfan pharmacokinetics in determining outcome.
Chandy M; Balasubramanian P; Ramachandran SV; Mathews V; George B; Dennison D; Krishnamoorthy R; Srivastava A
Bone Marrow Transplant; 2005 Nov; 36(10):839-45. PubMed ID: 16151422
[TBL] [Abstract][Full Text] [Related]
13. Busulfan disposition: the role of therapeutic monitoring in bone marrow transplantation induction regimens.
Grochow LB
Semin Oncol; 1993 Aug; 20(4 Suppl 4):18-25; quiz 26. PubMed ID: 8342071
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic drug monitoring for busulfan in plasma during conditioning chemotherapy for autologous stem cell transplantation in relapsed primary cerebral lymphoma.
Cull G; O'Halloran S; Ilett KF
Ther Drug Monit; 2010 Jun; 32(3):333-7. PubMed ID: 20386358
[TBL] [Abstract][Full Text] [Related]
15. Relationship of plasma pharmacokinetics of high-dose oral busulfan to the outcome of allogeneic bone marrow transplantation in children with thalassemia.
Pawlowska AB; Blazar BR; Angelucci E; Baronciani D; Shu XO; Bostrom B
Bone Marrow Transplant; 1997 Dec; 20(11):915-20. PubMed ID: 9422469
[TBL] [Abstract][Full Text] [Related]
16. Dose individualization of intravenous busulfan in pediatric patients undergoing bone marrow transplantation: impact and in vitro evaluation of infusion lag-time.
Neroutsos E; Athanasiadou I; Paisiou A; Zisaki K; Goussetis E; Archontaki H; Tsirigotis P; Kitra M; Grafakos S; Spyridonidis A; Dokoumetzidis A; Valsami G
J Pharm Pharmacol; 2021 Sep; 73(10):1340-1350. PubMed ID: 34244783
[TBL] [Abstract][Full Text] [Related]
17. Population pharmacokinetics of oral busulfan in children.
Schiltmeyer B; Klingebiel T; Schwab M; Mürdter TE; Ritter CA; Jenke A; Ehninger G; Gruhn B; Würthwein G; Boos J; Hempel G
Cancer Chemother Pharmacol; 2003 Sep; 52(3):209-16. PubMed ID: 12811512
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic disposition and clinical outcomes in infants and children receiving intravenous busulfan for allogeneic hematopoietic stem cell transplantation.
Schechter T; Finkelstein Y; Doyle J; Verjee Z; Moretti M; Koren G; Dupuis LL
Biol Blood Marrow Transplant; 2007 Mar; 13(3):307-14. PubMed ID: 17317584
[TBL] [Abstract][Full Text] [Related]
19. Individualizing high-dose oral busulfan: prospective dose adjustment in a pediatric population undergoing allogeneic stem cell transplantation for advanced hematologic malignancies.
Tran HT; Madden T; Petropoulos D; Worth LL; Felix EA; Sprigg-Saenz HA; Choroszy M; Danielson M; Przepiorka D; Chan KW
Bone Marrow Transplant; 2000 Sep; 26(5):463-70. PubMed ID: 11019834
[TBL] [Abstract][Full Text] [Related]
20. Association of busulfan area under the curve with veno-occlusive disease following BMT.
Dix SP; Wingard JR; Mullins RE; Jerkunica I; Davidson TG; Gilmore CE; York RC; Lin LS; Devine SM; Geller RB; Heffner LT; Hillyer CD; Holland HK; Winton EF; Saral R
Bone Marrow Transplant; 1996 Feb; 17(2):225-30. PubMed ID: 8640171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]